Stockscreener 앱 받기
134.86
0.79%
-0.89
전일 마감가:
$135.75
열려 있는:
$134.01
하루 거래량:
551.93K
Relative Volume:
1.05
시가총액:
$6.74B
수익:
$338.46M
순이익/손실:
$-310.96M
주가수익비율:
-20.65
EPS:
-6.53
순현금흐름:
$-132.82M
1주 성능:
+0.88%
1개월 성능:
+11.95%
6개월 성능:
+20.02%
1년 성능:
+54.36%
1일 변동 폭
$131.51
$136.10
1주일 범위
$123.50
$137.85
52주 변동 폭
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
AXSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
135.01 | 6.83B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.33 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.05 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.90 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
830.71 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.73 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-01 | 개시 | B. Riley Securities | Buy |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
AXSM: Morgan Stanley Raises Price Target and Maintains Overweigh - GuruFocus
AXSM: RBC Capital Raises Price Target and Maintains Outperform Rating | AXSM Stock News - GuruFocus
Is Axsome Therapeutics Set for More Gains After 54% Rally and Clinical Pipeline News? - Yahoo Finance
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Down After Earnings Miss - MarketBeat
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales - sharewise.com
Axsome anticipates expanded market access for SYMBRAVO and AUVELITY while advancing late-stage pipeline - MSN
Biologics Market Surges Toward $680B as FDA Accelerates Approval Pathways - The Globe and Mail
Axsome Therapeutics (NASDAQ:AXSM) Posts Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2025 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on Axsome Therapeutics to $198 From $189, Keeps Outperform Rating - MarketScreener
Axsome Therapeutics (AXSM): Net Margin Stays Negative as Growth Expectations Drive Up Valuation Debate - Yahoo Finance
Will Axsome Therapeutics Inc. stock go up soonWeekly Stock Recap & High Accuracy Trade Alerts - newser.com
Needham Reiterates Axsome Therapeutics (AXSM) Buy Recommendation - Nasdaq
Axsome: Q3 Earnings Snapshot - New Haven Register
Published on: 2025-11-04 04:14:34 - newser.com
How Axsome Therapeutics Inc. (19X) stock moves in volatile trading sessionsQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Can machine learning forecast Axsome Therapeutics Inc. recoveryQuarterly Growth Report & Accurate Intraday Trading Signals - newser.com
How Axsome Therapeutics Inc. stock compares to industry benchmarksWeekly Risk Summary & Proven Capital Preservation Tips - newser.com
Axsome Therapeutics Inc. stock trend forecast2025 Trading Volume Trends & Long-Term Growth Stock Strategies - newser.com
Decoding Axsome Therapeutics Inc (AXSM): A Strategic SWOT Insigh - GuruFocus
Axsome Therapeutics Reports Strong Q3 2025 Growth - TipRanks
Has Axsome Therapeutics Inc. formed a bullish divergenceTrade Risk Assessment & Precise Entry and Exit Recommendations - newser.com
Axsome Therapeutics Q3 2025 slides: Strong revenue growth amid pipeline expansion - Investing.com
Axsome Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Transcript : Axsome Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Axsome Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Axsome Therapeutics Q3 2025 reveals revenue beat, stock dips - Investing.com
Is Axsome Therapeutics Inc. forming a reversal pattern2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Axsome Therapeutics Saw Sales Jump But Losses Remain - Finimize
Market reaction to Axsome Therapeutics Inc.’s recent newsWeekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Axsome Therapeutics Q3 Net Loss Narrows, Revenue Rises - MarketScreener
Axsome Q3 2025 Financial Results: Revenue Beats, Loss WidensNews and Statistics - IndexBox
Axsome Therapeutics Reports 63% Revenue Growth in Q3 2025 - TipRanks
Earnings Flash (AXSM) Axsome Therapeutics Posts Q3 Net Loss $0.94 a Share, vs. FactSet Est of $0.82 Loss - MarketScreener
Earnings Flash (AXSM) Axsome Therapeutics, Inc. Reports Q3 Revenue $171.0M, vs. FactSet Est of $163.0M - MarketScreener
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Axsome Therapeutics Inc. stock momentum explainedJuly 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Axsome Therapeutics Q3 net product revenue jumps 63% - MarketScreener
Axsome Therapeutics Inc. recovery potential after sell offJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
Will Axsome Therapeutics Inc. stock sustain high P E ratios2025 Growth vs Value & Daily Stock Trend Reports - newser.com
Axsome Therapeutics Inc. stock volume spike explained2025 Dividend Review & Verified Entry Point Signals - newser.com
Historical volatility pattern of Axsome Therapeutics Inc. visualized2025 Key Lessons & Daily Technical Forecast Reports - newser.com
How Axsome Therapeutics Inc. (19X) stock reacts to Fed tighteningJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
How rising interest rates impact Axsome Therapeutics Inc. stock2025 Sector Review & Community Shared Stock Ideas - newser.com
Can Axsome Therapeutics Inc. stock continue upward trendJuly 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
What Wall Street predicts for Axsome Therapeutics Inc. stock pricePortfolio Profit Report & Short-Term Trading Opportunity Alerts - newser.com
Is a relief rally coming for Axsome Therapeutics Inc. holders2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Axsome Therapeutics Inc 주식 (AXSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 06 '25 |
Option Exercise |
8.02 |
19,220 |
154,144 |
26,449 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Option Exercise |
8.02 |
13,390 |
107,388 |
20,619 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Option Exercise |
8.02 |
12,774 |
102,447 |
20,003 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 06 '25 |
Sale |
120.17 |
19,220 |
2,309,667 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Sale |
118.77 |
13,390 |
1,590,330 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Sale |
118.84 |
12,774 |
1,518,062 |
7,229 |
1.29%
0.56%
자본화:
|
볼륨(24시간):